Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study.

European heart journal. Cardiovascular pharmacotherapy - 8 Feb 2025

Xiao Jun, Zhang Naiqi, Gao Ziting, Wei Yajing, Wei Hongye, Qiu Ziyi, Sundquist Kristina, Sundquist Jan, Ji Jianguang, Huang Wuqing

Abstract excerpt

BACKGROUND: Accumulating studies reported that several phosphodiesterases (PDEs) inhibitors might have cardiovascular benefits. OBJECTIVES: This study aimed to explore the relationship between genetically-predicted PDEs and ischaemia heart disease via drug target Mendelian randomization (MR) approach, and then examine the effect of inhibitors of identified target on the outcomes by using real-world data. METHODS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Incidence
Share to Mendelian Randomization Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myocardial Infarction

Share to Myocardial Ischemia

Share to Pharmacogenomic Variants

Share to Registries

Share to Risk Assessment

Share to Sweden

Source

Open in PubMed Open full text

Identifiers

PMID: 39424597
DOI: 10.1093/ehjcvp/pvae081
PMCID: PMC11805687

Genes

PDE5A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study.PMID 39424597Read ↗

Combination of QTL and GWAS to uncover the role of phosphodiesterases in ischemic heart diseaseSemantic proximity Read ↗

Effect of genetically proxied use of PDE5 inhibitors on risk of CHD: A drug target Mendelian Randomization studySemantic proximity Read ↗

Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study.Semantic proximity Read ↗

Primary Aldosteronism and Risk of Cardiovascular Outcomes: Genome-Wide Association and Mendelian Randomization Study.Semantic proximity Read ↗

Proteome-wide Mendelian Randomization Analysis Identified Potential Drug Targets for Myocardial InfarctionSemantic proximity Read ↗

Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study.Semantic proximity Read ↗

Identifying Potential Drug Targets in Coronary Atherosclerosis: Insights from the Druggable Genome and Mendelian Randomization.Semantic proximity Read ↗

Potential drug targets for myocardial infarction identified through Mendelian randomization analysis and Genetic colocalization.Semantic proximity Read ↗

Effect of disclosing a polygenic risk score for coronary heart disease on adverse cardiovascular events: 10-year follow-up of the MI-GENES randomized clinical trialSemantic proximity Read ↗

Disconnect Between Genes Associated With Ischemic Heart Disease and Targets of Ischemic Heart Disease Treatments.Semantic proximity Read ↗

Therapeutic targets for atherosclerotic coronary artery disease: druggable genome-wide Mendelian randomization analysis.Semantic proximity Read ↗

Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.